Post by ronykimm on Nov 30, 2021 7:52:41 GMT -5
The medication Zelboraf 240 mg is introduced as a monotherapy for the treatment of adult recipients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The zelboraf 240 mg therapy should be initiated and supervised by a qualified health specialist experienced in the use of anticancer medicinal products. Zelboraf may be administered orally with or without food, but consistent intake of both daily doses on an empty stomach need to be avoided. Prior to taking tablets of zelboraf, patients must have BRAF V600 mutation +Ve tumour status confirmed by a validated test.